September, 2009

**Society of Gynecologic Oncologists**

**Statement Regarding OVA1**

The Society of Gynecologic Oncologists (SGO) recognizes the importance of accurate detection of ovarian cancer and referral to gynecologic cancer specialists for women with ovarian masses. The OVA1 test, recently approved by the FDA, measures the levels of five proteins in blood samples from women with a known ovarian mass that have been reported to change when ovarian cancer is present, and may be a useful tool in identifying women who should be referred to a gynecologic oncologist for their ovarian cancer surgery.

As physicians who are expert in the care of women with gynecologic cancers, members of the SGO are supportive of scientific advances such as OVA1 that may help healthcare providers better detect when referral to a gynecologic oncologist is indicated. However, this test has not been approved for use as an ovarian cancer screening tool, nor has it been proven to result in early detection or reduce the risk of death from this disease. Results from the OVA1 test should not be interpreted independently, nor be used in place of a physician’s clinical assessment. Physicians are strongly encouraged to reference the SGO/ACOG Pelvic Mass Guidelines to determine an appropriate care plan for their patients.

SGO does not formally endorse or promote any specific products or brands as may be implied by in the product announcement.